TY  - GEN
AU  - Gurbel,P A
AU  - Bergmeijer,T O
AU  - Tantry,U S
AU  - ten Berg,J M
AU  - Angiolillo,D J
AU  - James,S
AU  - Lindahl,T L
AU  - Svensson,P
AU  - Jakubowski,J A
AU  - Brown,P B
AU  - Duvvuru,S
AU  - Sundseth,S
AU  - Walker,J R
AU  - Small,D
AU  - Moser,B A
AU  - Winters,K J
AU  - Erlinge,D
TI  - The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
SN  - 2567-689X
PY  - 2015///0615
KW  - Aged
KW  - Clinical Protocols
KW  - Clopidogrel
KW  - Coronary Artery Disease
KW  - drug therapy
KW  - Cytochrome P-450 CYP2C19
KW  - genetics
KW  - Female
KW  - Genotype
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Phenotype
KW  - Piperazines
KW  - administration & dosage
KW  - Platelet Aggregation
KW  - drug effects
KW  - Platelet Aggregation Inhibitors
KW  - Polymorphism, Genetic
KW  - Prasugrel Hydrochloride
KW  - Thiophenes
KW  - Ticlopidine
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1160/TH13-10-0891
ER  -